Is Thymoglobulin® a safe treatment for renal graft rejection in patients with HIV?
Jim Casey
This article has no abstract so we have provided the first paragraph of the full text.
Kidney transplants in HIV-infected patients result in a high rate of acute rejection, the reason for which is unknown. Antithymocyte globulin (Thymoglobulin®; Genzyme Corporation, Cambridge, MA), which contains antibodies against T-cell markers including CD4, is frequently used to manage rejection, but its safety has not been adequately assessed.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
